Meloxicam-13C6

• Description :

  Meloxicam-13C6 is 13C6-labeled Meloxicam (HY-B0261) . Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H360, H412

• Target :

  Apoptosis; Autophagy; COX; Isotope-Labeled Compounds; MMP

• Related Pathways :

  Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; Others

• Field of Research :

  Cancer; Inflammation/Immunology

• Purity :

  98.93

• Smiles :

  O=C(C1=C(O)[13C]2=[13CH][13CH]=[13CH][13CH]=[13C]2S(N1C)(=O)=O)NC3=NC=C(C)S3

• Molecular Formula :

  C8 13C6H13N3O4S2

• Molecular Weight :

  357.36

• Precautions :

  H301, H360, H412

• References & Citations :

  [1]Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40 (6) :980-9. |[2]Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14 (2) :2198-2206.|[3]Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32 (2) .

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported